Clinical disease stage related changes of serological factors in amyotrophic lateral sclerosis

References

• Küffner R, Zach N, Norel R, Hawe J, Schoenfeld D, Wang L, et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat Biotechnol. 2015;33:51–7.
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Simone IL, Capozzo R, Tortelli R, Leo A, D'Errico E, et al. An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosis. J Neurol. 2011;258:238–43.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Zhang M, Quiroz Zárate A, Jaffa M, Yu H, Cudkowicz ME, et al. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol. 2012;259:1923–8.
   PubMed Web of Science ®Google Scholar
• Kataoka H, Kiriyama T, Kobayashi Y, Horikawa H, Ueno S. Clinical outcomes and serum uric acid levels in elderly patients with amyotrophic lateral sclerosis aged >/= 70 years. Am J Neurodegener Dis. 2013;2:140–4.
   PubMedGoogle Scholar
• Zhang F, Zhang Q, Ke Y, Hao J, Lu L, Lu N, et al. Serum uric acid levels in patients with amyotrophic lateral sclerosis: a meta-analysis. Sci Rep. 2018;8:1100.
   PubMedGoogle Scholar
• Chiò A, Calvo A, Bovio G, Canosa A, Bertuzzo D, Galmozzi F, et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA Neurol. 2014;71:1134–42.
   PubMed Web of Science ®Google Scholar
• Sznajder J, SL-W M, Klek S. The influence of the initial state of nutrition on the lifespan of patients with amyotrophic lateral sclerosis (ALS) during home enteral nutrition. Nutr Hosp. 2016;33:3–7.
   PubMed Web of Science ®Google Scholar
• Paillisse C, Lacomblez L, Dib M, Bensimon G, Garcia-Acosta S, Meininger V. Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6:37–44.
   PubMed Web of Science ®Google Scholar
• Lawton KA, Brown MV, Alexander D, Li Z, Wulff JE, Lawson R, et al. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:362–70.
   PubMed Web of Science ®Google Scholar
• Bozik ME, Mitsumoto H, Brooks BR, Rudnicki SA, Moore DH, Zhang B, et al. A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:406–13.
   PubMed Web of Science ®Google Scholar
• Patin F, Corcia P, Madji Hounoum B, Veyrat-Durebex C, Respaud E, Piver E, et al. Biological follow-up in amyotrophic lateral sclerosis: decrease in creatinine levels and increase in ferritin levels predict poor prognosis. Eur J Neurol. 2015;22:1385–90.
   PubMed Web of Science ®Google Scholar
• Oh SI, Baek S, Park JS, Piao L, Oh KW, Kim SH. Prognostic role of serum levels of uric acid in amyotrophic lateral sclerosis. J Clin Neurol. 2015;11:376–82.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Hirayama T, Takazawa T, Kawabe K, Iwasaki Y. Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med. 2012;51:1501–8.
   PubMed Web of Science ®Google Scholar
• Chen X, Guo X, Huang R, Zheng Z, Chen Y, Shang HF. An exploratory study of serum creatinine levels in patients with amyotrophic lateral sclerosis. Neurol Sci. 2014;35:1591–7.
   PubMed Web of Science ®Google Scholar
• Zheng Z, Guo X, Wei Q, Song W, Cao B, Huang R, et al. Serum uric acid level is associated with the prevalence but not with survival of amyotrophic lateral sclerosis in a Chinese population. Metab Brain Dis. 2014;29:771–5.
   PubMed Web of Science ®Google Scholar
• Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D, Bittar R, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70:1004–9.
   PubMed Web of Science ®Google Scholar
• Dorst J, Kuhnlein P, Hendrich C, Kassubek J, Sperfeld AD, Ludolph AC. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol. 2011;258:613–7.
   PubMed Web of Science ®Google Scholar
• Huang R, Guo X, Chen X, Zheng Z, Wei Q, Cao B, et al. The serum lipid profiles of amyotrophic lateral sclerosis patients: a study from south-west China and a meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:359–65.
   PubMed Web of Science ®Google Scholar
• Ahmed RM, Highton-Williamson E, Caga J, Thornton N, Ramsey E, Zoing M, et al. Lipid metabolism and survival across the frontotemporal dementia-amyotrophic lateral sclerosis spectrum: Relationships to eating behavior and cognition. J Alzheimers Dis. 2018;61:773–83.
   PubMed Web of Science ®Google Scholar
• Mariosa D, Hammar N, Malmström H, Ingre C, Jungner I, Ye W, et al. Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: a more than 20-year follow-up of the Swedish AMORIS cohort. Ann Neurol. 2017;81:718–28.
   PubMed Web of Science ®Google Scholar
• Chiò A, Calvo A, Ilardi A, Cavallo E, Moglia C, Mutani R, et al. Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology. 2009;73:1681–5.
   PubMed Web of Science ®Google Scholar
• Rafiq MK, Lee E, Bradburn M, McDermott CJ, Shaw PJ. Effect of lipid profile on prognosis in the patients with amyotrophic lateral sclerosis: Insights from the olesoxime clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:478–84.
   PubMed Web of Science ®Google Scholar
• Ferraro D, Consonni D, Fini N, Fasano A, Del Giovane C, Mandrioli J. Amyotrophic lateral sclerosis: a comparison of two staging systems in a population-based study. Eur J Neurol. 2016;23:1426–32.
   PubMed Web of Science ®Google Scholar
• Strong MJ. The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2008;9:323–38.
   PubMed Web of Science ®Google Scholar
• Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456–77.
   PubMed Web of Science ®Google Scholar
• Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain. 2012;135:847–52.
   PubMed Web of Science ®Google Scholar
• Chen X, Wei QQ, Chen Y, et al. Clinical Staging of Amyotrophic Lateral Sclerosis in Chinese Patients. Front Neurol. 2018;9:442.
   PubMed Web of Science ®Google Scholar
• Kori M, Aydin B, Unal S, Arga KY, Kazan D. Metabolic biomarkers and neurodegeneration: a pathway enrichment analysis of Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Omics. 2016;20:645–61.
   PubMed Web of Science ®Google Scholar
• Keizman D, Ish-Shalom M, Berliner S, Maimon N, Vered Y, Artamonov I, et al. Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress? J Neurol Sci. 2009;285:95–9.
   PubMed Web of Science ®Google Scholar
• Lawton KA, Cudkowicz ME, Brown MV, Alexander D, Caffrey R, Wulff JE, et al. Biochemical alterations associated with ALS. Amyotroph Lateral Scler. 2012;13:110–8.
   PubMed Web of Science ®Google Scholar
• Ghasemzadeh N, Nyberg F, Hjerten S. Highly selective artificial gel antibodies for detection and quantification of biomarkers in clinical samples. II. Albumin in body fluids of patients with neurological disorders. J Sep Sci. 2008;31:3954–8.
   PubMed Web of Science ®Google Scholar
• Yang JW, Kim SM, Kim HJ, Kim JE, Park KS, Kim SH, et al. Hypolipidemia in patients with amyotrophic lateral sclerosis: a possible gender difference? J Clin Neurol. 2013;9:125–9.
   PubMed Web of Science ®Google Scholar
• Nagase M, Yamamoto Y, Miyazaki Y, Yoshino H. Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. Redox Rep. 2016;21:104–12.
   PubMed Web of Science ®Google Scholar
• Delaye JB, Patin F, Piver E, Bruno C, Vasse M, Vourc'h P, et al. Low IDL-B and high LDL-1 subfraction levels in serum of ALS patients. J Neurol Sci. 2017;380:124–7.
   PubMed Web of Science ®Google Scholar
• Sutedja NA, van der Schouw YT, Fischer K, Sizoo EM, Huisman MHB, Veldink JH, et al. Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2011;82:638–42.
   PubMed Web of Science ®Google Scholar
• Proudfoot M, Jones A, Talbot K, Al-Chalabi A, Turner MR. The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:414–25.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13–21.
   PubMed Web of Science ®Google Scholar
• Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009;66:1460–8.
   PubMed Web of Science ®Google Scholar
• Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008;65:716–23.
   PubMed Web of Science ®Google Scholar